
Eileen M Joyce

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7405247/publications.pdf Version: 2024-02-01



FILFEN M LOVCE

#	Article	IF	CITATIONS
1	Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia. JAMA Psychiatry, 2022, 79, 260.	11.0	44
2	Cognitive function in early-phase schizophrenia-spectrum disorder: IQ subtypes, brain volume and immune markers. Psychological Medicine, 2022, , 1-10.	4.5	3
3	Disrupted reward processing in Parkinson's disease and its relationship with dopamine state and neuropsychiatric syndromes: a systematic review and meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 555-562.	1.9	15
4	The organisational climate of NHS Early Intervention Services (EIS) for psychosis: a qualitative analysis. BMC Health Services Research, 2022, 22, 509.	2.2	4
5	Basal Ganglia Pathways Associated With Therapeutic Pallidal Deep Brain Stimulation for Tourette Syndrome. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging, 2021, 6, 961-972.	1.5	12
6	Deconstructing depression and negative symptoms of schizophrenia; differential and longitudinal immune correlates, and response to minocycline treatment. Brain, Behavior, and Immunity, 2021, 91, 498-504.	4.1	28
7	Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. Brain Communications, 2021, 3, fcab168.	3.3	33
8	A Unified Functional Network Target for Deep Brain Stimulation in Obsessive-Compulsive Disorder. Biological Psychiatry, 2021, 90, 701-713.	1.3	41
9	Inhibitory Control on a Stop Signal Task in Tourette Syndrome before and after Deep Brain Stimulation of the Internal Segment of the Globus Pallidus. Brain Sciences, 2021, 11, 461.	2.3	4
10	A systematic review of the effects of psychiatric medications on social cognition. BMC Psychiatry, 2021, 21, 597.	2.6	10
11	Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2020, 34, 3-78.	4.0	259
12	Outcome Measures for Functional Neurological Disorder: A Review of the Theoretical Complexities. Journal of Neuropsychiatry and Clinical Neurosciences, 2020, 32, 33-42.	1.8	65
13	Outcome measurement in functional neurological disorder: a systematic review and recommendations. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 638-649.	1.9	77
14	A unified connectomic target for deep brain stimulation in obsessive-compulsive disorder. Nature Communications, 2020, 11, 3364.	12.8	199
15	Impaired automatic but intact volitional inhibition in primary tic disorders. Brain, 2020, 143, 906-919.	7.6	35
16	Voluntary tic suppression and the normalization of motor cortical beta power in Gilles de la Tourette syndrome: an <scp>EEG</scp> study. European Journal of Neuroscience, 2019, 50, 3944-3957.	2.6	17
17	Globus pallidal deep brain stimulation for Tourette syndrome: Effects on cognitive function. Parkinsonism and Related Disorders, 2019, 69, 14-18.	2.2	5
18	A Randomized Trial Directly Comparing Ventral Capsule and Anteromedial Subthalamic Nucleus Stimulation in Obsessive-Compulsive Disorder: Clinical and Imaging Evidence for Dissociable Effects. Biological Psychiatry, 2019, 85, 726-734.	1.3	152

EILEEN M JOYCE

#	Article	IF	CITATIONS
19	Exploring every ethical avenue. Commentary: The Moral Obligation to Prioritize Research Into Deep Brain Stimulation Over Brain Lesioning Procedures for Severe Enduring Anorexia Nervosa. Frontiers in Psychiatry, 2019, 10, 326.	2.6	6
20	Are socioenvironmental factors associated with psychotic symptoms in people with first-episode psychosis? A cross-sectional study of a West London clinical sample. BMJ Open, 2019, 9, e030448.	1.9	10
21	Minocycline for negative symptoms of schizophrenia and possible mechanistic actions: the BeneMin RCT. Efficacy and Mechanism Evaluation, 2019, 6, 1-66.	0.7	2
22	The CIRCuiTS study (Implementation of cognitive remediation in early intervention services): protocol for a randomised controlled trial. Trials, 2018, 19, 183.	1.6	16
23	Development and clinimetric assessment of a nurse-administered screening tool for movement disorders in psychosis. BJPsych Open, 2018, 4, 404-410.	0.7	3
24	T86. COGNITIVE SUBTYPES IN FIRST-EPISODE PSYCHOSIS: AN EMPIRICAL LONGITUDINAL STUDY OF RELATIONSHIP TO COGNITIVE, SYMPTOM AND FUNCTIONAL OUTCOMES. Schizophrenia Bulletin, 2018, 44, S148-S148.	4.3	0
25	The benefit of minocycline on negative symptoms of schizophrenia in patients with recent-onset psychosis (BeneMin): a randomised, double-blind, placebo-controlled trial. Lancet Psychiatry,the, 2018, 5, 885-894.	7.4	133
26	The component structure of the scales for the assessment of positive and negative symptoms in first-episode psychosis and its dependence on variations in analytic methods. Psychiatry Research, 2018, 270, 869-879.	3.3	15
27	Motor cortical excitability during voluntary inhibition of involuntary tic movements. Movement Disorders, 2018, 33, 1804-1809.	3.9	25
28	Organic psychosis: The pathobiology and treatment of delusions. CNS Neuroscience and Therapeutics, 2018, 24, 598-603.	3.9	34
29	T46. TARGETING THE IMMUNE SYSTEM TO TREAT DEPRESSION AND NEGATIVE SYMPTOMS IN SCHIZOPHRENIA. Schizophrenia Bulletin, 2018, 44, S131-S131.	4.3	1
30	More haste less speed: A meta-analysis of thinking latencies during planning in people with psychosis. Psychiatry Research, 2017, 258, 576-582.	3.3	2
31	Are persistent delusions in schizophrenia associated with aberrant salience?. Schizophrenia Research: Cognition, 2016, 4, 32-38.	1.3	14
32	Bilateral globus pallidus stimulation for severe Tourette's syndrome: a double-blind, randomised crossover trial. Lancet Neurology, The, 2015, 14, 595-605.	10.2	155
33	The benefit of minocycline on negative symptoms in early-phase psychosis in addition to standard care - extent and mechanism (BeneMin): study protocol for a randomised controlled trial. Trials, 2015, 16, 71.	1.6	8
34	Multidisciplinary treatment for functional neurological symptoms: a prospective study. Journal of Neurology, 2014, 261, 2370-2377.	3.6	79
35	The role of alexithymia in the development of functional motor symptoms (conversion disorder). Journal of Neurology, Neurosurgery and Psychiatry, 2014, 85, 1132-1137.	1.9	108
36	The role of the right inferior frontal gyrus in the pathogenesis of post-stroke psychosis. Journal of Neurology, 2014, 261, 600-603.	3.6	35

EILEEN M JOYCE

#	Article	IF	CITATIONS
37	Cognitive function in schizophrenia: insights from intelligence research. British Journal of Psychiatry, 2013, 203, 161-162.	2.8	20
38	Neural and Behavioral Correlates of Aberrant Salience in Individuals at Risk for Psychosis. Schizophrenia Bulletin, 2013, 39, 1328-1336.	4.3	180
39	Dysconnectivity in the Frontoparietal Attention Network in Schizophrenia. Frontiers in Psychiatry, 2013, 4, 176.	2.6	53
40	The Relationship Between IQ, Memory, Executive Function, and Processing Speed in Recent-Onset Psychosis: 1-Year Stability and Clinical Outcome. Schizophrenia Bulletin, 2010, 36, 400-409.	4.3	90
41	The assessment of dangerous and severe personality disorder: lessons from a randomised controlled trial linked to qualitative analysis. Journal of Forensic Psychiatry and Psychology, 2009, 20, 132-146.	1.0	46
42	Critique of the assessment phase of the DSPD programme. Journal of Forensic Psychiatry and Psychology, 2009, 20, 151-154.	1.0	0
43	IQ as a predictor of functional outcome in schizophrenia: A longitudinal, four-year study of first-episode psychosis. Schizophrenia Research, 2009, 107, 55-60.	2.0	108
44	Duration of untreated psychosis and social function: 1-year follow-up study of first-episode schizophrenia. British Journal of Psychiatry, 2008, 193, 203-209.	2.8	114
45	Cognitive heterogeneity in schizophrenia. Current Opinion in Psychiatry, 2007, 20, 268-272.	6.3	144
46	Gaze strategies during planning in first-episode psychosis Journal of Abnormal Psychology, 2007, 116, 589-598.	1.9	20
47	Cognitive heterogeneity in first-episode schizophrenia. British Journal of Psychiatry, 2005, 187, 516-522.	2.8	120
48	The impact of olanzapine on attitude to medication and quality of life in schizophrenia. Psychiatric Bulletin, 2001, 25, 378-381.	0.3	6
49	West London first-episode study of schizophrenia. British Journal of Psychiatry, 2000, 177, 207-211.	2.8	172
50	â€~Adults with Parkinson's disease and hallucinations or delusions can have treatment with clozapine if they need to'. BJ Psych Advances, 0, , 1-3.	0.7	0